Table 1 Clinical characteristics of three groups

Age (years)

22.2 ± 3.3

20.5 ± 3.7

28.12 ± 7.5

0.005^*

Onset (years)

19.8 ± 2.4

10.5 ± 4.1

15.72 ± 8.3

0.354

ASM

 Beginning age (years)

20.3 ± 3.1

16.7 ± 5.2

17.5 ± 8.5

0.365

 VPA, n (%)

0

1 (10%)

9 (36%)

 TPM, n (%)

0

1 (10%)

3 (12%)

 CBZ, n (%)

0

0

12 (48%)

 LEV, n (%)

7 (70%)

4 (40%)

11 (44%)

 OXC, n (%)

1 (10%)

2 (20%)

9 (36%)

 LTG, n (%)

1 (10%)

3 (30%)

7 (28%)

 PB, n (%)

0

0

3 (12%)

LH

11.48 ± 9.53

9.81 ± 5.48

6.65 ± 3.72

0.022^*

FSH

6.08 ± 1.20

6.08 ± 1.57

6.81 ± 3.24

0.396

LH/FSH

1.86 ± 1.37

1.56 ± 0.58

1.24 ± 1.20

0.135

PRL

17.27 ± 8.04

21.74 ± 5.67

34.17 ± 45.9

0.167

E2

54.66 ± 31.12

37.41 ± 9.89

67.25 ± 83.46

0.456

P

0.41 ± 0.28

0.37 ± 0.27

0.88 ± 1.76

0.277

T

0.50 ± 0.09

0.36 ± 0.17

0.21 ± 0.11

 < 0.001^*

DHEA-S

8.35 ± 2.79

7.45 ± 3.45

3.76 ± 1.93

 < 0.001^*

BMI

20.9 ± 1.7

24.7 ± 6.7

21.9 ± 3.0

0.822

Overweight, n (%)

1(10%)

5(50%)

7(28%)

GLU-0

4.85 ± 0.30

5.23 ± 0.41

5.03 ± 0.39

0.413

GLU-2 h

5.63 ± 1.11

6.81 ± 2.99

7.24 ± 1.78

0.041^*

INS-0

8.33 ± 2.01

19.13 ± 19.89

8.61 ± 3.55

0.589

INS-2 h

50.72 ± 19.95

114.19 ± 135.55

58.75 ± 33.30

0.844

FINS, n (%)

3(30%)

6(60%)

6(24%)

HOMA-IR, n (%)

1(10%)

5(50%)

5(25%)